Huons, a Korean total healthcare company, is launching its vaccine business through a partnership with global pharmaceutical giant Sanofi.
Huons announced Wednesday that it signed a domestic distribution and co-promotion agreement with Sanofi covering five injectable vaccine products at a ceremony held at the company's headquarters in Pangyo, Seongnam, Gyeonggi Province.
Starting July 1, Huons will handle domestic distribution and promotion for five vaccines: influenza vaccines Vaxigrip and Efluelda, Adacel for diphtheria, tetanus and pertussis in adults, Avaxim 160 for hepatitis A, and MenQuadfi for meningococcal disease. Both companies expect the combination of their respective strengths to create synergies in targeting the Korean vaccine market.
Sanofi supplies medicines and vaccines that treat and protect millions of people worldwide, while Huons has built expertise in injectable drug sales and cold chain logistics in the domestic market.
In preparation for the partnership, Huons recently established a dedicated Vaccine Business Division to systematically drive its vaccine operations. The company plans to leverage its experienced injectable drug sales professionals and existing customer network to provide Korean medical professionals and patients with world-class vaccine accessibility.
Drawing on cold chain management technology and logistics infrastructure built through its experience distributing refrigerated injectables such as Meritc Injection and Hudaxin Injection, Huons aims to ensure stable delivery of temperature-sensitive vaccines to medical institutions nationwide.
Huons plans to position the vaccine business as a new growth engine based on its strategic partnerships with multinational pharmaceutical companies, expanding its pipeline and strengthening sustainable growth drivers.
"The collaboration with Sanofi, a company recognized worldwide for its scientific credibility and quality in the vaccine field, will be an important turning point for Huons to grow as a global-level public health partner," Huons CEO Song Soo-young said. "By combining Sanofi's innovative solutions with Huons' pharmaceutical sales know-how, we will set new standards in the domestic vaccine market."